Want to see AU:PHX full AI Analyst Report?
PHX Stock Chart & Stats
AU$0.10
<AU$0.01(5.00%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(5.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.20
Previous CloseN/A
Volume723.89K
Average Volume (3M)486.13K
Market Cap
AU$48.81M
Enterprise ValueAU$79.67M
Total Cash (Recent Filing)AU$2.57M
Total Debt (Recent Filing)AU$540.00K
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.52%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding668,618,650
10 Day Avg. Volume858,165
30 Day Avg. Volume486,131
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)3.46
Price to Sales (P/S)10.58
P/FCF Ratio100.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageDebt-to-equity of about 0.02 in 2026 versus 0.06 in 2025 indicates limited leverage, while equity rose to about 23.3M. This gives PHX more capacity to absorb operating setbacks and fund initiatives without substantial debt-service pressure.
Expanded Capital BaseAssets expanded from about 18.8M to 27.3M year over year, alongside higher equity. A larger capital base can support ongoing operations and provide financial flexibility over the next several quarters, although its value depends on restoring profitability.
Positive 2026 Cash GenerationPositive 2026 operating cash flow of about 0.83M and free cash flow of about 0.81M show that PHX generated cash despite reported losses. If maintained, this could reduce dependence on external funding and support resilience, though the historical swing makes durability unproven.
Bears Say
Revenue ContractionRevenue fell about 19.2% year over year in 2026, signaling a materially weaker top-line outcome. Sustained contraction would reduce operating leverage, constrain investment capacity, and make it harder for PHX to recover margins and reach profitability.
Negative Gross MarginGross margin turned slightly negative at about -0.9% in 2026, versus strong gross profit in 2025, while operating performance weakened sharply. This reversal indicates the reported revenue base was not covering direct costs, obstructing sustainable earnings.
Volatile Cash FlowCash generation swung from approximately 8.1M of operating and free cash outflow in 2025 to positive results in 2026, while 2026 free cash flow still declined 17.7% year over year. This volatility weakens confidence in durable self-funding.
PharmX Technologies News
PHX FAQ
What was PharmX Technologies Limited’s price range in the past 12 months?
PharmX Technologies Limited lowest share price was AU$0.06 and its highest was AU$0.20 in the past 12 months.
What is PharmX Technologies Limited’s market cap?
PharmX Technologies Limited’s market cap is AU$48.81M.
When is PharmX Technologies Limited’s upcoming earnings report date?
PharmX Technologies Limited’s upcoming earnings report date is Feb 25, 2027 which is in 124 days.
How were PharmX Technologies Limited’s earnings last quarter?
PharmX Technologies Limited released its earnings results on Aug 26, 2026. The company reported -AU$0.002 earnings per share for the quarter.
Is PharmX Technologies Limited overvalued?
According to Wall Street analysts PharmX Technologies Limited’s price is currently Overvalued.
Does PharmX Technologies Limited pay dividends?
PharmX Technologies Limited pays a Notavailable dividend of AU$0.007 which represents an annual dividend yield of 6.52%. See more information on PharmX Technologies Limited dividends here
What is PharmX Technologies Limited’s EPS estimate?
PharmX Technologies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmX Technologies Limited have?
PharmX Technologies Limited has 668,618,650 shares outstanding.
What happened to PharmX Technologies Limited’s price movement after its last earnings report?
PharmX Technologies Limited reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of PharmX Technologies Limited?
Currently, no hedge funds are holding shares in AU:PHX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PharmX Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.60%
12-Months-Change
Fundamentals
Return on Equity
-9.39%
Trailing 12-Months
Asset Growth
44.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PharmX Technologies Limited
PharmX Technologies Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It also operates PharmX, an electronic ordering and invoicing gateway; PharmX Marketplace, an e-commerce ordering platform; PharmX Analytics which provides insights for operations of supplier and pharmacy customers. The company was formerly known as Corum Group Limited and changed its name to PharmX Technologies Limited in October 2023. PharmX Technologies Limited was incorporated in 1950 and is headquartered in Sydney, Australia.
Technical Analysis
Beamtree Holdings Ltd
―
MedAdvisor Limited
―
Alcidion Group Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―